Sector News

Allergan toys with $5B women's health sale to boost bottom-feeding shares

April 4, 2018
Life sciences

How times have changed. Just five short months after Allergan’s CEO assured investors that the company wouldn’t break up, it’s reportedly weighing options for its women’s health unit.

The Dublin drugmaker has met with advisers about a potential sale, sources told Bloomberg. And if Allergan does sell the business, which would likely draw interest from private equity firms, it could bring in more than $5 billion.

Another option? Sell off the portfolio in parts, just as Teva recently did with its own women’s health business. As RBC Capital Markets analyst Randall Stanicky pointed out in a note to clients, the Israeli pharma unloaded those assets quickly and at “attractive valuations.”

“We think that there would be buyers here,” he wrote.

Speaking of Stanicky, he’s been calling for an Allergan breakup for months—and for a women’s health sale in particular. Back in November, he predicted a transaction could generate $6 billion, although that was before a liver-safety review of uterine fibroids drug Esmya in Europe cast doubt on the med’s future and pushed back an FDA decision date on the product.

The way he sees it, examining options for women’s health “is a logical first step,” for Allergan as it works to lift its badly battered shares.

Initially, Allergan’s management thought it could boost those shares with cost cuts, which it rolled out last year after a Restasis patent decision paved the way for early copycats to the company’s No. 2 seller. But the bad news kept rolling in—complete with word of Mylan’s plans for a biosimilar threat to top-selling Botox—forcing Saunders to walk back his previous “no breakup” assurances.

Saunders’ “message was clear that all strategic options are being evaluated,” Stanicky wrote after hearing the skipper speak at a March investor conference, adding that Allergan was taking on the task “with a sense of urgency.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.